Last reviewed · How we verify
NCT04072250
Surgery for Recurrent Intrahepatic Cholangiocarcinoma
trial testing hepatectomy in Cholangiocarcinoma, Intrahepatic in 216 participants. Completed in 30 October 2018.
1 October 2018
Quick facts
| Lead sponsor | Chang Gung Memorial Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 216 |
| Start date | 1 June 2017 |
| Primary completion | 1 October 2018 |
| Estimated completion | 30 October 2018 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- hepatectomy
Conditions studied
- Cholangiocarcinoma, Intrahepatic — all drugs for Cholangiocarcinoma, Intrahepatic →
- Recurrence Cholangiocarcinoma — all drugs for Recurrence Cholangiocarcinoma →
- Re-hepatectomy — all drugs for Re-hepatectomy →
Sponsor
Chang Gung Memorial Hospital
Who can join
Adults 18 to 75, any sex, with Cholangiocarcinoma, Intrahepatic or Recurrence Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators retrospectively reviewed the participants suffering from recurrent intrahepatic cholangiocarcinoma after curative resection and aimed to explore the predictive factors for recurrence and clarify the potential benefit of repeat hepatectomy or/with metastasectomy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04072250
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of hepatectomy
Trials testing the same drug.
- NCT04163887 — Effect of the Laparoscopic Approach in Reducing Postoperative Severe Complications Following Hepatectomy for Colorectal · NA · unknown
- NCT05450874 — A Novel MSE Score to Predict rHCC Patients · completed
- NCT05402644 — Hepatectomy for Early-stage HCC Patients With CSPH · completed
- NCT04709718 — Surgical Management of Giant Hepatic Hemangioma · completed
- NCT04748081 — The Major Bleeding Risk Following Hepatectomy · completed
Other recruiting trials for Cholangiocarcinoma, Intrahepatic
Currently open trials in the same condition.
- NCT05210322 — Percutaneous Cholangiopancreatoscopy Registry · active not recruiting
- NCT04634058 — PD-L1 Antibody Combined With CTLA-4 Antibody for Patients With Advanced Intrahepatic Cholangiocarcinoma Who Progressed A · Phase 2 · active not recruiting
Other Chang Gung Memorial Hospital trials
Trials by the same sponsor.
- NCT07419789 — Precision Care for Older Persons · NA · not yet recruiting
- NCT07248345 — Virtual Reality Intervention for Family Caregivers of Persons Living With Dementia · NA · not yet recruiting
- NCT07036978 — Metabolomic and Immune-Microbiome Profiling for Unresectable Pancreatic Cancer · not yet recruiting
- NCT07489833 — Metabolomic Pathways and Traditional Chinese Medicine Body Constitution in Cancer-related Fatigue · not yet recruiting
- NCT07496528 — The ACURE Trial: Acupuncture for Colorectal Recovery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04072250 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chang Gung Memorial Hospital
- Last refreshed: 13 September 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04072250.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing